The psychological consequences and quality of life in adults with growth hormone deficiency

Growth Hormone and IGF Research

Volumn 10, Issue SUPPL. B, 2000, Pages

  McGauley, G ^a,b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b BROADMOOR HOSPITAL   (United Kingdom)

Author keywords

Adult onset growth hormone deficiency; Depression; Growth hormone deficiency; Quality of life

Indexed keywords

GROWTH HORMONE;

ANXIETY; CLINICAL FEATURE; COGNITION; DEPRESSION; FATIGUE; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPOPHYSIS DISEASE; MEMORY; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SELF CARE; SOCIAL ISOLATION; SOCIAL SUPPORT;

EID: 0033903947     PISSN: 10966374     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1096-6374(00)80012-X     Document Type: Review

References (37)

1. The growth hormone deficiency syndrome in adults
2. Quality of life assessment before and after growth hormone treatment in adults with growth hormone deficiency
3. Psychological well-being before and after growth hormone treatment in adults with growth hormone deficiency
4. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH
5. Growth hormone treatment of adults with growth hormone deficiency: Results of a 13-month placebo controlled cross-over study
6. On behalf of the investigators. Growth hormone replacement therapy in adult hypopituitary patients with growth hormone deficiency: Combined data from 12 European placebo-controlled clinical trials
7. Quality of life of adults with growth hormone (GH) deficiency: Response to treatment with recombinant human GH in a placebo-controlled 21-month trial
8. Replacement treatment with biosynthetic human growth hormone in growth hormone-deficient hypopituitary adults
9. The Australian multicenter trial of growth hormone (GH) treatment in GH-deficient adults
10. One year follow up of quality of life in adults with untreated growth hormone deficiency
11. GH replacement in 1034 growth hormone deficient hypopituitary adults: Demographic and clinical characteristics, dosing and safety
12. The development, reliability and validity of a disease-specific quality of life model for adults with growth hormone deficiency
13. Quality of life, body composition and muscle strength in adult growth hormone deficiency: The influence of growth hormone replacement therapy for up to 3 years
14. A comparison of two psychiatric screening tests
15. The SCL-90: An outpatient psychiatric rating scale-preliminary report
16. The CPRS: Development and application of a psychiatric rating scale
17. The Hospital Anxiety and Depression Scale
18. A comparative psychiatric assessment of patients with chronic fatigue syndrome and muscle disease
19. The development of a novel scale to assess life fulfilment as part of the further refinement of a quality of life model for epilepsy
20. Measuring the impact of epilepsy: The development of a novel scale
21. Development of a questionnaire to assess the quality of life of adults with growth hormone deficiency
22. The QoL-AGHDA: An instrument for the assessment of quality of life in adults with growth hormone deficiency
23. Decreased psychological well-being in adult patients with growth hormone deficiency
24. The burden of illness of hypopituitary adults with growth hormone deficiency
25. Psychiatric morbidity in adults with hypopituitarism
26. The quality of life of adults with growth hormone deficiency: Comparison with diabetic patients and control subjects
27. An account of the quality of life of patients after treatment for non-functioning pituitary tumours
28. The effects of two doses of replacement growth hormone on the biochemical, body composition and psychological profiles of growth hormone deficient adults
29. Effects of physiological growth hormone (GH) therapy on cognition and quality of life in patients with adult-onset GH deficiency
30. Beneficial effects of long-term GH replacement therapy on quality of life in adults with GH deficiency
31. Impact of recombinant human growth hormone (RH-GH) treatment on psychiatric, neuropsychological and clinical profiles of GH deficient adults. A placebo-controlled trial
32. Growth hormone treatment affects brain neurotransmitters and thyroxine